Form 8-K - Current report:
SEC Accession No. 0001104659-25-065785
Filing Date
2025-07-03
Accepted
2025-07-03 16:10:34
Documents
12
Period of Report
2025-07-01
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2519837d1_8k.htm   iXBRL 8-K 25584
  Complete submission text file 0001104659-25-065785.txt   188643

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA mrsn-20250701.xsd EX-101.SCH 3011
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrsn-20250701_lab.xml EX-101.LAB 34239
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrsn-20250701_pre.xml EX-101.PRE 22356
14 EXTRACTED XBRL INSTANCE DOCUMENT tm2519837d1_8k_htm.xml XML 3557
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38129 | Film No.: 251105653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)